Osteologix has recently made strong moves and passed major milestones which have been primary motivators for RedChip’s upgraded rating.
In the past week, the company announced that it raised approximately $5 million in private placement financing. The CEO commented, “Management believes that the funds received from this financing will enable us to continue operations into the second half of next year, beyond our next critical developmental milestone, which is the release of data results from our Phase II study in the treatment of osteoporosis.”
The company has also completed its enrollment in the “Strong Study”, completed its phase II clinical trial, introduced a new and improved dosage form of Strontium, and treated osteoporosis in several European countries.
Their product’s dual action ability to increase bone density while reducing bone resorption, sets the company apart from the rest of the industry and makes it a compelling choice in the pharmaceutical market.
Let us hear your thoughts below: